10 recruiting, 4 unknown, 3 terminated, 2 completed. 8 Phase 2, 3 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Erdheim-Chester Disease: new trials by email Literature Review of Erdheim-Chester Disease trials Research Report on Erdheim-Chester Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| Q702 for the Treatment of Patients With Hematologic Malignancies Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration - Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma | Phase 1 | Recruiting | Mayo Clinic | 46 | 2025-08-27 | 2025-10-10 |
| ECD-Score: a Study on Erdheim-Chester Disease Erdheim-Chester Disease (ECD) | Recruiting | Meyer Children's Hospital IRCCS | 1000 | 2024-12-23 | 2026-03-06 | |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| Histiocytic Disorder Follow-up Study Histiocytosis, Langerhans Cell Histiocytosis | Recruiting | University of Alabama at Birmingham | 6000 | 2022-09-01 | 2026-06-12 | |
| The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation HLX208 - Langerhans Cell Histiocytosis, Erdheim-Chester Disease | Phase 2 | Unknown | Shanghai Henlius Biotech | 25 | 2021-12-06 | 2023-08-08 |
| In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET [68Ga]-Pentixafor - Non-Hodgkin Lymphoma, Multiple Myeloma | Early Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2021-10-01 | 2026-02-05 |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders Cobimetinib - Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma | Phase 2 | Recruiting | Carl Allen | 90 | 2021-04-19 | 2025-09-18 |
| Subtypes and Prognostic Factors in Erdheim-Chester Disease Investigation of BRAF mosaicism - Erdheim-Chester Disease | Not applicable | Unknown | Meyer Children's Hospital IRCCS | 70 | 2020-09-15 | 2024-03-19 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors HH2710 - Advanced Tumors, Melanoma | Phase 1 / Phase 2 | Terminated | Haihe Biopharma Co., Ltd. | 37 | 2020-01-07 | 2024-07-19 |
| GWAS and EWAS in Patients With Erdheim-Chester Disease Presence of polymorphisms - Erdheim-Chester Disease | Unknown | Augusto Vaglio | 300 | 2019-07-17 | 2024-03-27 | |
| Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases online surveys - Supportive Care Needs of Caregivers | Recruiting | Memorial Sloan Kettering Cancer Center | 250 | 2019-06-14 | 2026-07-02 | |
| Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations Dabrafenib Mesylate, Quality-of-Life Assessment, Questionnaire Administration - Erdheim-Chester Disease | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2019-01-04 | 2021-03-17 | |
| Biomarker for Farber Disease (BioFarber) Farber's Lipogranulomatosis, Ceramidase Deficiency | Withdrawn | CENTOGENE GmbH Rostock | 2018-08-20 | 2023-02-13 | ||
| Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses Erdheim-Chester Disease | Recruiting | Memorial Sloan Kettering Cancer Center | 500 | 2017-10-26 | 2026-01-08 | |
| Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement F-choline PET Scan, FDG-PET, biopsy - Erdheim-Chester Disease, Langerhans Cell Histiocytosis | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2015-11-01 | 2018-08-29 | |
| Lenalidomide for Adult Histiocyte Disorders Lenalidomide - Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 12 | 2015-08-01 | 2026-07-23 |
| International Rare Histiocytic Disorders Registry (IRHDR) Registry study - Rare Histiocytic Disorders (RHDs), Erdheim-Chester Disease (ECD) | Recruiting | The Hospital for Sick Children | 400 | 2014-10-01 | 2025-06-24 | |
| Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease Erdheim-Chester Disease | Unknown | Groupe Hospitalier Pitie-Salpetriere | 20 | 2014-03-01 | 2016-10-28 | |
| Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Tocilizumab - Erdheim-Chester Disease | Phase 2 | Terminated | Ospedale San Raffaele | 3 | 2012-11-01 | 2016-02-10 |
Showing 20 of 22. Sign in to see all of them.
Histiocytosis, Langerhans-Cell (8) · Histiocytosis, Sinus (5) · Histiocytic Sarcoma (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Multiple Myeloma (3) · Colorectal Neoplasms (2) · Glioma (2) · Hematologic Neoplasms (2) · Laryngeal Neoplasms (2) · Melanoma (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Ovarian Neoplasms (2)
Hemic and Lymphatic Diseases (22) · Histiocytosis, Non-Langerhans-Cell (22) · Lymphatic Diseases (22) · Histiocytosis (21) · Lung Diseases (11) · Respiratory Tract Diseases (11) · Lung Diseases, Interstitial (9) · Neoplasms by Histologic Type (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Neoplasms (6) · Hematologic Diseases (5) · Hemorrhagic Disorders (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5)
Biopsy (2) · cobimetinib (2) · dabrafenib (2) · trametinib (2) · 68Ga-pentixafor (1) · Bevacizumab (1) · CCT239065 (1) · Cetuximab (1) · Disulfides (1) · Immunoglobulin G (1) · Lenalidomide (1) · Magnetic Resonance Spectroscopy (1) · Sirolimus (1) · Specimen Handling (1) · Valproic Acid (1)
Memorial Sloan Kettering Cancer Center (4) · Cancer Research UK (2) · Meyer Children's Hospital IRCCS (2) · Augusto Vaglio (1) · CENTOGENE GmbH Rostock (1) · Carl Allen (1) · Dana-Farber Cancer Institute (1) · Groupe Hospitalier Pitie-Salpetriere (1) · Haihe Biopharma Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · National Human Genome Research Institute (NHGRI) (1) · Ospedale San Raffaele (1) · Shanghai Henlius Biotech (1)
United States (15) · Italy (5) · France (3) · United Kingdom (3) · China (2) · Germany (2) · Spain (2) · Argentina (1) · Canada (1) · Czechia (1) · Egypt (1) · India (1) · Netherlands (1) · Poland (1)
Eli Diamond, MD (3) · Anton Nosov, MD (1) · Augusto Vaglio, Medical Doctor (1) · Carl E Allen, MD, PhD (1) · Eli L. Diamond, MD, PhD (1) · Eric Jacobsen, MD (1) · Filip Janku (1) · Fleur Cohen Aubart, MD, PhD (1) · Gaurav Goyal, MD (1) · Jithma P. Abeykoon, MD (1) · Julien Haroche, MD, PhD (1) · Kevin J O'Brien, C.R.N.P. (1) · Lorenzo Dagna, MD (1) · Matthew Krebs (1) · Matthew Krebs, Dr (1)
PMID 33057928, PMID 37311055, PMID 39626273, PMID 41389341
P30CA016672 (1)